hVIVO (HVO) Share Price, News & Analysis

Company Overview

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

Key Stats

• Today's Range: 9.80 to 10.20
• 50-Day Range: 9.50 to 11.90
• 52-Week Range: 6.50 to 30.45
• Volume: 1.10 million shs
• Average Volume: 3.00 million shs
• Market Capitalization: £69.75 million
• P/E Ratio: 654.84
• Dividend Yield: 0.02%
• Price Target: GBX 28
• Consensus Rating: Buy

hVIVO Stock Analysis - MarketRank™

hVIVO scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

hVIVO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

hVIVO has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of hVIVO is 654.84, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 269.61.

Price to Earnings Ratio vs. Sector

The P/E ratio of hVIVO is 654.84, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 82.41.

Price to Book Value per Share Ratio

hVIVO has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HVO.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

hVIVO pays a meaningful dividend of 2.02%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

hVIVO does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of hVIVO is 12.90%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for HVO.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.71

News Sentiment

hVIVO has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for hVIVO this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, hVIVO insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.43% of the stock of hVIVO is held by insiders.

Percentage Held by Institutions

Only 4.57% of the stock of hVIVO is held by institutions.

HVO Stock Analysis - Frequently Asked Questions

How have HVO shares performed this year?

hVIVO's stock was trading at GBX 20.50 at the beginning of the year. Since then, HVO shares have decreased by 50.5% and is now trading at GBX 10.15.

How were hVIVO's earnings last quarter?

hVIVO plc (LON:HVO) announced its quarterly earnings data on Thursday, April, 10th. The company reported $1.69 EPS for the quarter. hVIVO had a trailing twelve-month return on equity of 47.93% and a net margin of 25.96%.

How do I buy shares of hVIVO?

Shares of HVO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of hVIVO own?

Based on aggregate information from My MarketBeat watchlists, some other companies that hVIVO investors own include ValiRx (VAL), boohoo group (BOO), Petrofac (PFC), Lloyds Banking Group (LLOY), Falanx Group (FLX), IQE (IQE) and Rolls-Royce Holdings plc (RR).

Company Calendar

• Last Earnings: 4/10/2025
• Today: 9/03/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:HVO
• Previous Symbol: LON:RVG
• CIK: N/A
• Web: hvivo.com
• Phone: +44-20-77561300
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for hVIVO: GBX 28
• High Price Target: GBX 35
• Low Price Target: GBX 21
• Potential Upside/Downside: +175.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 0.02
• Trailing P/E Ratio: 654.84
• Forward P/E Ratio: 6.55
• P/E Growth: N/A
• Net Income: £17.84 million
• Net Margins: 25.96%
• Pretax Margin: N/A
• Return on Equity: 47.93%
• Return on Assets: 11.97%

Debt

• Debt-to-Equity Ratio: 33.86
• Current Ratio: 1.61
• Quick Ratio: 1.16

Sales & Book Value

• Annual Sales: £62.73 million
• Price / Sales: 1.11
• Cash Flow: GBX 2.06 per share
• Price / Cash Flow: 4.94
• Book Value: GBX 5.56 per share
• Price / Book: 1.83

Miscellaneous

• Outstanding Shares: 687,216,000
• Free Float: N/A
• Market Cap: £69.75 million
• Optionable: Not Optionable
• Beta: 0.97